EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort

Dimitrios Papantoniou iD, Malin Grönberg, Espen Thiis-Evensen, Halfdan Sorbye, Kalle Landerholm, Staffan Welin, Eva Tiensuu Janson

Endocrine-Related Cancer · 01.03.2023 · 30 (3)

DOI: 10.1530/erc-22-0316 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, erschienen am 01.03.2023. Verfasst von Dimitrios Papantoniou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small intestinal neuroendocrine tumours (Si-NET) are often studied as a uniform group. Proliferation index Ki-67 influences prognosis and determines tumour grade. We hypothesized that Si-NET grade 2 (G2) tumours, which have a higher Ki-67 than G1 tumours, might benefit less from established treatments for metastatic disease. We conducted a retrospective cohort study of 212 patients with metastatic Si-NET G2 treated in two Swedish hospitals during 20 years (2000–2019). Median cancer-specific survival on first-line somatostatin analogues (SSA) was 77 months. Median progression-free survival (PFS) was 12.4 months when SSA was given as monotherapy and 19 months for all patients receiving first-line SSA. PFS after SSA dose escalation was 6 months in patients with radiological progression. Treatment efficacies of SSA and peptide receptor radionuclide treatment (PRRT) were studied separately in patients with Ki-67 of 3–5%, 5–10% and 10–20%. For SSA, PFS was significantly shorter at higher Ki-67 levels (31, 18 and 10 months, respectively), while there was only a minor difference in PFS for PRRT (29, 25 and 25 months). Median PFS for sequential treatment with interferon-alpha (IFNα), everolimus and chemotherapy was 6, 5 and 9 months. IFNα seemed to be effective in tumours with low somatostatin–receptor expression. In conclusion, established treatments appeared effective in Si-NET G2, despite their higher proliferation index compared to G1 tumours. However, efficacy of SSA but not PRRT was reduced at higher Ki-67 levels. SSA dose escalation provided limited disease stabilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotideIntestinal NeoplasmsRetrospective StudiesRadioisotopesStomach NeoplasmsHumansPancreatic NeoplasmsKi-67 AntigenTreatment OutcomeSomatostatin

Stichwörter der Autor:innen

Ki-67PRRTSi-NETgrade 2interferonpeptide receptor radionuclide treatmentsmall intestinal neuroendocrine tumourssomatostatin analoguessomatostatin receptor negative

Substanzen

OctreotideKi-67 AntigenSomatostatinRadioisotopes

Autor:innen und Institutionen

  • Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden.
  • Department of Oncology, Ryhov County Hospital, Jönköping, Sweden.
  • Oslo University Hospital, Rikshospitalet, Deptartment of Organ Transplant, Oslo, Norway.
  • Haukeland Hospital, Deptartment of Oncology, Bergen, Norway.
  • University of Bergen, Deptartment of Clinical Medicine, Bergen, Norway.
  • Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

ORCID-Profile: Dimitrios Papantoniou

Zitieren

APA

Papantoniou, D., Grönberg, M., Thiis-Evensen, E., Sorbye, H., Landerholm, K., Welin, S., & Tiensuu Janson, E. (2023). Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. Endocrine-Related Cancer, 30(3). https://doi.org/10.1530/erc-22-0316

Vancouver

Papantoniou D, Grönberg M, Thiis-Evensen E, Sorbye H, Landerholm K, Welin S, et al. Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. Endocrine-Related Cancer. 2023;30(3). doi:10.1530/erc-22-0316

BibTeX
@article{Papantoniou2023,
  author = {Papantoniou, Dimitrios and Grönberg, Malin and Thiis-Evensen, Espen and Sorbye, Halfdan and Landerholm, Kalle and Welin, Staffan and Tiensuu Janson, Eva},
  title = {Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort},
  journal = {Endocrine-Related Cancer},
  year = {2023},
  volume = {30},
  number = {3},
  doi = {10.1530/erc-22-0316}
}
Kostenlos starten →